Belimumab in systemic lupus erythematosus
Belimumab is the only approved biological agent for the treatment of systemic lupus erythematosus (SLE). It is a fully humanized IgG1γ monoclonal antibody directed against soluble B lymphocyte stimulator (BLyS). It is indicated as an add-on therapy for the treatment of adult patients with active, au...
Saved in:
Main Author: | Ankita Srivastava (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer Medknow Publications,
2016-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Belimumab for systemic lupus erythematosus - Focus on lupus nephritis
by: Marlene Plüß, et al.
Published: (2022) -
Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab
by: Guzman M, et al.
Published: (2020) -
Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus
by: A. G. Tolkushin, et al.
Published: (2018) -
Cost-effectiveness analysis of Belimumab in patients with systemic lupus erythematosus in Spain
by: Silvia Díaz-Cerezo, et al.
Published: (2015) -
Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain
by: Cevey M, et al.
Published: (2019)